NDAINJECTIONINJECTABLE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bretylium tosylate is an injectable antiarrhythmic agent approved by FDA in 1986 for the treatment of ventricular arrhythmias. It is administered intravenously and works through sympathomimetic and antiarrhythmic mechanisms to restore normal heart rhythm. This is a legacy small-molecule product with a long clinical history.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal Part D claims data, suggesting a niche, declining market with a small commercial footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on bretylium tosylate offers minimal career growth opportunity given the zero linked job openings and approaching loss of exclusivity. This assignment is suitable for early-career roles seeking niche expertise or experienced professionals managing product wind-down.
Brand ManagerField Sales Representative
Worked on BRETYLIUM TOSYLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.